Journal
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
Volume 158, Issue 4, Pages 317-325Publisher
KARGER
DOI: 10.1159/000333100
Keywords
Allergic rhinitis; Cataract; Corticosteroids; Fluticasone furoate; Glaucoma; Intranasal corticosteroids; Intraocular pressure; Nasal spray; Ocular allergy; Ophthalmic safety profile
Categories
Funding
- GlaxoSmithKline
- Allergan
- Merck
- ALK-Abello
Ask authors/readers for more resources
Allergic rhinoconjunctivitis (ARC) presents as nasal symptoms, eye watering and additional signs of ocular allergy (e. g. itchy/burning eyes). Intranasal corticosteroids (INSs) are the most effective treatment for the nasal symptoms of seasonal allergic rhinitis (SAR; based on 4 meta-analyses) and are considered first-line therapy when nasal congestion forms a substantial component of the patient's rhinitis symptoms. Clinical trial evidence shows that INSs also provide some relief from ocular symptoms of SAR and seasonal ARC in adults. INSs probably alleviate eye watering, the main ocular symptom of SAR, by relieving nasal congestion. Other ocular symptoms also improve with INSs. The mechanism for this effect is unknown, but might relate to naso-ocular reflex reduction. There are limited data on ocular safety with INSs. However, the literature supports the use of INSs over several months as there appears to be no considerable increase in the risk of ocular hypertension or glaucoma. Copyright (C) 2012 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available